Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy.Robert J. Motzer, Daniel Yick Chin Heng, Yanfang Liu et al.|Journal of Clinical Oncology|2021Cited by 6
SLC25A21 Correlates with the Prognosis of Adult Acute Myeloid Leukemia through Inhibiting the Growth of Leukemia Cells Via Downregulating CXCL8Shujuan Wang, Wenyi Lu, Yu Liu et al.|Blood|2024Cited by 0